Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Oxid Med Cell Longev. 2017;2017:1485283. doi: 10.1155/2017/1485283. Epub 2017 Jun 18.
Targeted cancer therapies, involving tyrosine kinase inhibitors and monoclonal antibodies, for example, have recently led to substantial prolongation of survival in many metastatic cancers. Compared with traditional chemotherapy and radiotherapy, where reactive oxygen species (ROS) have been directly linked to the mediation of cytotoxic effects and adverse events, the field of oxidative stress regulation is still emerging in targeted cancer therapies. Here, we provide a comprehensive review regarding the current evidence of ROS-mediated effects of antibodies and tyrosine kinase inhibitors, use of which has been indicated in the treatment of solid malignancies and lymphomas. It can be concluded that there is rapidly emerging evidence of ROS-mediated effects of some of these compounds, which is also relevant in the context of drug resistance and how to overcome it.
例如，靶向癌症治疗方法，包括酪氨酸激酶抑制剂和单克隆抗体，最近导致许多转移性癌症的生存时间显著延长。与传统的化疗和放疗相比，活性氧 (ROS) 已被直接与细胞毒性作用和不良事件的介导相关联，在靶向癌症治疗中，氧化应激调节领域仍在不断发展。在这里，我们全面回顾了 ROS 介导的抗体和酪氨酸激酶抑制剂的作用的现有证据，这些抗体和酪氨酸激酶抑制剂已被用于治疗实体恶性肿瘤和淋巴瘤。可以得出结论，有越来越多的证据表明这些化合物中的一些具有 ROS 介导的作用，这在耐药性及其克服方面也具有相关性。
